Literature DB >> 24167674

The roles of ARID1A in gynecologic cancer.

Tsui-Lien Mao1, Ie-Ming Shih.   

Abstract

One of the exciting findings in recent cancer genome studies is the discovery of somatic mutations in several chromatin remodeling genes. These studies not only illuminate the emerging roles of chromatin remodeling in the pathogenesis of human cancer but also provide molecular genetic basis of aberrant epigenomic regulation as one of the key mechanisms driving cancer development. This is because chromatin remodeling influences a variety of DNA activities such as replication, transcription, repair, methylation, and recombination. Among the mutated chromatin remodeling genes reported, ARID1A is frequently mutated in a variety of human cancers, especially in endometrium-related neoplasms including ovarian clear cell carcinoma, ovarian endometrioid carcinomas, and uterine endometrioid carcinomas, all of which arise from endometrial epithelium. This review will summarize the recent advances in studying the roles of ARID1A mutations in gynecologic cancers with special emphasis on how this new knowledge will further extend our understanding of the pathogenesis of endometrium-related carcinomas.

Entities:  

Keywords:  ARID1A; BAF250a; Chromatin remodeling; Endometriosis; Ovarian cancer

Year:  2013        PMID: 24167674      PMCID: PMC3805919          DOI: 10.3802/jgo.2013.24.4.376

Source DB:  PubMed          Journal:  J Gynecol Oncol        ISSN: 2005-0380            Impact factor:   4.401


  54 in total

Review 1.  Chromatin remodelling during development.

Authors:  Lena Ho; Gerald R Crabtree
Journal:  Nature       Date:  2010-01-28       Impact factor: 49.962

2.  Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas.

Authors:  Kimberly C Wiegand; Anna F Lee; Osama M Al-Agha; Christine Chow; Steve E Kalloger; David W Scott; Christian Steidl; Sam M Wiseman; Randy D Gascoyne; Blake Gilks; David G Huntsman
Journal:  J Pathol       Date:  2011-05-18       Impact factor: 7.996

3.  hSNF5/INI1-deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities.

Authors:  F Bourdeaut; P Fréneaux; B Thuille; A Lellouch-Tubiana; A Nicolas; J Couturier; G Pierron; C Sainte-Rose; C Bergeron; R Bouvier; X Rialland; V Laurence; J Michon; X Sastre-Garau; O Delattre
Journal:  J Pathol       Date:  2007-02       Impact factor: 7.996

4.  Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Authors:  Siân Jones; Tian-Li Wang; Ie-Ming Shih; Tsui-Lien Mao; Kentaro Nakayama; Richard Roden; Ruth Glas; Dennis Slamon; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Science       Date:  2010-09-08       Impact factor: 47.728

Review 5.  The SWI/SNF complex and cancer.

Authors:  D Reisman; S Glaros; E A Thompson
Journal:  Oncogene       Date:  2009-02-23       Impact factor: 9.867

6.  Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions.

Authors:  Bin Guan; Min Gao; Chen-Hsuan Wu; Tian-Li Wang; Ie-Ming Shih
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

7.  Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer.

Authors:  Junya Fukuoka; Takeshi Fujii; Joanna H Shih; Tatiana Dracheva; Daoud Meerzaman; Audrey Player; Kyeong Hong; Sharon Settnek; Ajay Gupta; Kenneth Buetow; Stephen Hewitt; William D Travis; Jin Jen
Journal:  Clin Cancer Res       Date:  2004-07-01       Impact factor: 12.531

Review 8.  Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints.

Authors:  D Llobet; J Pallares; A Yeramian; M Santacana; N Eritja; A Velasco; X Dolcet; X Matias-Guiu
Journal:  J Clin Pathol       Date:  2008-10-31       Impact factor: 3.411

9.  Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis.

Authors:  David N Reisman; Janiece Sciarrotta; Weidong Wang; William K Funkhouser; Bernard E Weissman
Journal:  Cancer Res       Date:  2003-02-01       Impact factor: 12.701

10.  Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types.

Authors:  Siân Jones; Meng Li; D Williams Parsons; Xiaosong Zhang; Jelle Wesseling; Petra Kristel; Marjanka K Schmidt; Sanford Markowitz; Hai Yan; Darell Bigner; Ralph H Hruban; James R Eshleman; Christine A Iacobuzio-Donahue; Michael Goggins; Anirban Maitra; Sami N Malek; Steve Powell; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Hum Mutat       Date:  2011-11-23       Impact factor: 4.878

View more
  20 in total

1.  ARID1A expression in early stage colorectal adenocarcinoma: an exploration of its prognostic significance.

Authors:  Lik Hang Lee; Eran Sadot; Sinisa Ivelja; Efsevia Vakiani; Jaclyn F Hechtman; Christopher J Sevinsky; David S Klimstra; Fiona Ginty; Jinru Shia
Journal:  Hum Pathol       Date:  2016-03-02       Impact factor: 3.466

2.  Expression of PIK3IP1 in the murine uterus during early pregnancy.

Authors:  Hanna E Teasley; Hye Jin Chang; Tae Hoon Kim; Bon Jeong Ku; Jae-Wook Jeong
Journal:  Biochem Biophys Res Commun       Date:  2017-12-28       Impact factor: 3.575

3.  Checkpoint kinase 1 inhibitors as targeted molecular agents for clear cell carcinoma of the ovary.

Authors:  Hiroshi Kobayashi; Hiroshi Shigetomi; Chiharu Yoshimoto
Journal:  Oncol Lett       Date:  2015-05-26       Impact factor: 2.967

Review 4.  Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis.

Authors:  Claudio Luchini; Nicola Veronese; Marco Solmi; Hanbyoul Cho; Jae-Hoon Kim; Angela Chou; Anthony J Gill; Sheila F Faraj; Alcides Chaux; George J Netto; Kentaro Nakayama; Satoru Kyo; Soo Young Lee; Duck-Woo Kim; George M Yousef; Andreas Scorilas; Gregg S Nelson; Martin Köbel; Steve E Kalloger; David F Schaeffer; Hai-Bo Yan; Feng Liu; Yoshihito Yokoyama; Xianyu Zhang; Da Pang; Zsuzsanna Lichner; Giuseppe Sergi; Enzo Manzato; Paola Capelli; Laura D Wood; Aldo Scarpa; Christoph U Correll
Journal:  Oncotarget       Date:  2015-11-17

5.  Loss of ARID1A expression predicts poor survival prognosis in gastric cancer: a systematic meta-analysis from 14 studies.

Authors:  Lin Yang; Sheng Wei; Rongxian Zhao; Yingxing Wu; Hong Qiu; Huihua Xiong
Journal:  Sci Rep       Date:  2016-06-29       Impact factor: 4.379

6.  Increased proliferation in atypical hyperplasia/endometrioid intraepithelial neoplasia of the endometrium with concurrent inactivation of ARID1A and PTEN tumour suppressors.

Authors:  Ayse Ayhan; Tsui-Lien Mao; Yohan Suryo Rahmanto; Felix Zeppernick; Hiroshi Ogawa; Ren-Chin Wu; Tian-Li Wang; Ie-Ming Shih
Journal:  J Pathol Clin Res       Date:  2015-05-27

7.  BRG1 and BRM loss selectively impacts RB and P53, respectively: BRG1 and BRM have differential functions in vivo.

Authors:  Stefanie B Marquez-Vilendrer; Sudhir K Rai; Sarah Jb Gramling; Li Lu; David N Reisman
Journal:  Oncoscience       Date:  2016-12-21

Review 8.  ARID1A Variations in Cholangiocarcinoma: Clinical Significances and Molecular Mechanisms.

Authors:  Shankun Zhao; Youwen Xu; Weizhou Wu; Pan Wang; Yichao Wang; Hao Jiang; Jie Zhu
Journal:  Front Oncol       Date:  2021-06-25       Impact factor: 6.244

9.  Loss of Tumor Suppressor ARID1A Protein Expression Correlates with Poor Prognosis in Patients with Primary Breast Cancer.

Authors:  Hyun Deuk Cho; Jong Eun Lee; Hae Yoen Jung; Mee-Hye Oh; Ji-Hye Lee; Si-Hyong Jang; Kyung-Ju Kim; Sun Wook Han; Sung Yong Kim; Han Jo Kim; Sang Byung Bae; Hyun Ju Lee
Journal:  J Breast Cancer       Date:  2015-12-23       Impact factor: 3.588

Review 10.  Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives.

Authors:  Shinya Matsuzaki; Kiyoshi Yoshino; Yutaka Ueda; Satoko Matsuzaki; Mamoru Kakuda; Akiko Okazawa; Tomomi Egawa-Takata; Eiji Kobayashi; Tadashi Kimura
Journal:  Cancer Cell Int       Date:  2015-12-15       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.